Solventum Corporation (NYSE:SOLV) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Solventum Corporation (NYSE:SOLV) have received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $84.25.

A number of equities analysts have commented on SOLV shares. Rothschild & Co Redburn started coverage on shares of Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Weiss Ratings raised shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a research note on Thursday, May 14th. Finally, Wells Fargo & Company lowered their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th.

Solventum Trading Up 3.0%

SOLV stock opened at $77.83 on Friday. The firm has a market cap of $13.48 billion, a P/E ratio of 9.54, a P/E/G ratio of 1.17 and a beta of 0.69. The business’s 50 day moving average is $74.37 and its 200-day moving average is $74.58. Solventum has a 1-year low of $62.38 and a 1-year high of $88.20. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter last year, the company posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities analysts anticipate that Solventum will post 6.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

Several large investors have recently made changes to their positions in the stock. Ballast Advisors LLC bought a new stake in shares of Solventum during the first quarter worth $63,000. Parallel Advisors LLC lifted its position in shares of Solventum by 46.6% in the first quarter. Parallel Advisors LLC now owns 4,019 shares of the company’s stock worth $262,000 after purchasing an additional 1,277 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Solventum by 2.2% in the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock worth $438,000 after purchasing an additional 144 shares in the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Solventum in the first quarter worth $230,000. Finally, Wellington Grp LLC lifted its position in shares of Solventum by 48.7% in the first quarter. Wellington Grp LLC now owns 6,561 shares of the company’s stock worth $428,000 after purchasing an additional 2,150 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.